All In Biotech

Drug Trial Radar · NCT07071532

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder

A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of ABBV-932 in Adult Subjects With Bipolar Disorder

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Aug 20, 2026

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the adverse events and how oral ABBV-932 moves through the body when given with oral Itraconazole in adult participants with bipolar disorder.

Conditions

  • Bipolar Disorder

Interventions

  • ABBV-932Drug

    Oral Capsule

  • ItraconazoleDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
  2. Time to Cmax (Tmax) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
  3. Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
  4. Apparent terminal phase elimination rate constant (β) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
  6. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
  7. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
  8. Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 61 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel Collaborative Neuroscience Research /ID# 282784

    Los Alamitos, California · Recruiting

  • Acpru /Id# 276951

    Grayslake, Illinois · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.